Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review details the process and advantages of drug repurposing, highlighting its potential as a cost-effective and expedited alternative to traditional drug development while summarizing various strategies and successful examples, and exploring related regulatory challenges.

In this pilot study on treating dorsal wrist ganglion, PRP injection showed limited effectiveness at 1-year follow-up compared to aspiration alone, with most PRP-treated patients experiencing ganglion recurrence, suggesting that an RCT would need at least 46 patients per group to further assess PRP's utility.

Abatacept may help some people with alopecia areata regrow hair.

In this study, 93% of patients with inflammatory arthritis remained on the adalimumab biosimilar ABP 501 for 24 weeks after switching from the originator, with some switching back due to adverse reactions or reduced effectiveness.

This article discusses the symptoms, diagnostic methods, and complications associated with achalasia and reports no new clinical findings.

This review suggests that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) have potential benefits for dermatologic conditions but may also cause adverse skin reactions and impact surgical outcomes.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

This article discusses a proprietary botanical lotion with potential to reverse chemotherapy-induced alopecia, restore hair cycles, and improve patient wellbeing; however, it reports no new clinical results.

This article provides contact details and affiliations for Amy M. Karch and Fred E. Karch; it presents no new research findings.

In this study, higher doses of daunorubicin during induction therapy significantly improved complete remission rates in young adults with acute myeloid leukemia.

This study found that while no predictive factors for response to vismodegib were identified, longer treatment duration was associated with a lower risk of relapse in basal cell carcinoma patients.

This study found that neoadjuvant chemotherapy followed by interval debulking surgery led to better quality of life and lower perioperative morbidity compared to primary debulking surgery in advanced epithelial ovarian cancer patients with high tumor load.

This study describes the positive effects of the JAK inhibitor ruxolitinib in treating autoimmune manifestations in three patients with autoimmune polyendocrine syndrome type-1 over a period of at least 30 months, with excellent tolerance and no adverse events observed.

This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.

This article highlights the importance of recognizing, preventing, and reporting adverse drug reactions to the FDA's MedWatch program, but it presents no new research findings.

In this case report, the authors describe a child with treatment-resistant alopecia areata who successfully responded to leflunomide and anthralin, proposing this combination as a potentially cost-effective alternative for managing recalcitrant cases by possibly inhibiting the JAK/STAT pathway.

In this study, Zusanli acupoint injections of metoclopramide significantly improved dyspeptic symptoms in patients with functional dyspepsia more than oral domperidone, with no adverse reactions in either group.

The combination of gemcitabine and vinorelbine is effective and safe for treating elderly patients with advanced breast cancer previously treated with anthracyclines and taxanes.

This study found that the PPARγ modulator NAC-GED-0507-Levo may protect hair follicles from chemotherapy-induced damage, potentially offering a strategy to address irreversible hair loss in cancer patients.

This review examines the adverse skin reactions associated with antipsychotic medications and reports no new clinical findings, but suggests discussing management strategies to improve patient compliance.

This scoping review found that most of the 64 alopecia areata patients treated with upadacitinib in existing reports experienced significant hair regrowth, with mild side effects, but the authors call for larger studies to confirm these outcomes.

This study suggests that the neurosteroid allopregnanolone may play a crucial role in how ethanol affects neurons related to alcohol addiction vulnerability.

This article discusses ongoing and planned clinical chemoprevention trials for various agents and combinations but reports no new results; it highlights promising new agents and the evolving focus on molecular pathways.

In this study, autologous platelet-rich plasma was associated with improved burn wound healing in a 45-year-old male, showing potential as an adjunctive therapy, but broader trials are needed to confirm its effectiveness.

In this retrospective study at Toyama University Hospital, amoxapine was reported to significantly improve semen volume, sperm concentration, and total sperm count in 17 men with ejaculatory disorders, with no observed side effects over an average of 13 months of therapy.

In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.

This study suggests that PrEP implants for HIV prevention are potentially acceptable among gay and bisexual men, with positive attitudes toward implant features and minor insertion-related effects.

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.